AG-01 is under clinical development by A&G Pharmaceutical and currently in Phase I for Malignant Mesothelioma. According to GlobalData, Phase I drugs for Malignant Mesothelioma have a 77% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AG-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AG-01 is under development for the treatment of triple negative breast cancer, mesothelioma and non-small cell lung cancer. It is administered through parenteral route.
A&G Pharmaceutical overview
A&G Pharmaceutical operates as a medical device company that discovers and develops theranostics products. It offers personalized medicines for cancer, integrated Rx-Dx products, biomarkers, GP88-based breast cancer diagnostic testing kits, GP88 diagnostic kits, and anti-GP88 monoclonal antibody therapeutic products. It also provides breast cancer treatments, progranulin, molecular diagnostic testing, targeted therapeutics, companion diagnostics, new treatment paradigm and long-term diagnostic products. A&G Pharmaceutical offers clinical and preclinical programs, clinical diagnostic testing, disease recurrence monitoring, and laboratory testing services. The company’s products are used in screening, detection, and treatment of various cancers. A&G Pharmaceutical is headquartered in Columbia, Maryland, the US.
For a complete picture of AG-01’s drug-specific PTSR and LoA scores, buy the report here.